Amundi Sells 207,560 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Amundi reduced its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 27.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 558,514 shares of the medical equipment provider's stock after selling 207,560 shares during the quarter. Amundi owned about 0.29% of Zimmer Biomet worth $50,501,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. PNC Financial Services Group Inc. grew its stake in shares of Zimmer Biomet by 9.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 161,195 shares of the medical equipment provider's stock valued at $14,495,000 after buying an additional 13,883 shares in the last quarter. Morningstar Investment Management LLC raised its position in Zimmer Biomet by 235.4% during the fourth quarter. Morningstar Investment Management LLC now owns 57,865 shares of the medical equipment provider's stock worth $5,204,000 after acquiring an additional 40,610 shares in the last quarter. Douglas Lane & Associates LLC lifted its stake in Zimmer Biomet by 6.7% in the fourth quarter. Douglas Lane & Associates LLC now owns 460,178 shares of the medical equipment provider's stock valued at $41,379,000 after acquiring an additional 28,818 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its stake in Zimmer Biomet by 257.2% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 34,370 shares of the medical equipment provider's stock valued at $3,091,000 after acquiring an additional 24,748 shares during the last quarter. Finally, Robertson Stephens Wealth Management LLC bought a new position in shares of Zimmer Biomet in the 4th quarter valued at about $1,131,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Trading Up 0.3%

Shares of NYSE:ZBH opened at $94.20 on Monday. The business's 50 day simple moving average is $88.84 and its 200 day simple moving average is $89.85. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $108.29. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. The company has a market capitalization of $18.22 billion, a P/E ratio of 24.47, a P/E/G ratio of 2.77 and a beta of 0.45.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, July 31st. Investors of record on Thursday, June 25th were given a dividend of $0.24 per share. The ex-dividend date of this dividend was Thursday, June 25th. This represents a $0.96 annualized dividend and a yield of 1.0%. Zimmer Biomet's dividend payout ratio is currently 24.94%.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the firm's stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the transaction, the insider directly owned 27,251 shares of the company's stock, valued at $2,252,022.64. This trade represents a 15.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.28% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ZBH has been the subject of a number of research analyst reports. Canaccord Genuity Group set a $83.00 price target on Zimmer Biomet in a report on Wednesday, April 29th. Wells Fargo & Company cut their price objective on Zimmer Biomet from $98.00 to $90.00 and set an "equal weight" rating for the company in a research report on Wednesday, April 29th. Leerink Partners started coverage on Zimmer Biomet in a research note on Monday, April 13th. They set a "hold" rating and a $101.00 target price for the company. Wall Street Zen raised Zimmer Biomet from a "hold" rating to a "buy" rating in a report on Saturday, July 25th. Finally, Weiss Ratings cut Zimmer Biomet from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, twelve have issued a Hold rating and four have given a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $102.00.

About Zimmer Biomet

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.